Treats idiopathic pulmonary fibrosis (IPF). ANDA 219227, held by Apotex. Nintedanib Esylate.
As of Nov 16, 2026, ANDA 219227 (Nintedanib Esylate), held by Apotex, was first approved by FDA on Apr 2, 2026, with 0 approved supplements and 0 published complete response letters.
Nintedanib capsules are a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype 1.1 Idiopathic Pulmonary Fibrosis Nintedanib capsules are indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Nintedanib capsules are indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2026 | Original application | Approved |
| Nintedanib EsylateEQ 100MG BASE · capsule;oral | Nintedanib Esylate | Rx |
| Nintedanib EsylateEQ 150MG BASE · capsule;oral | Nintedanib Esylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters